LIPO (Lipella Pharmaceuticals) Current Accrued Expense: $0.14 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lipella Pharmaceuticals Current Accrued Expense?

Lipella Pharmaceuticals LIPO Current Accrued Expense is $0.14 Mil as of Sep. 2025. The stock has 1 warning sign investors should review.

Lipella Pharmaceuticals's Current Accrued Expense for the quarter that ended in Sep. 2025 was $0.14 Mil.

Lipella Pharmaceuticals's quarterly Current Accrued Expense declined from Mar. 2025 ($0.36 Mil) to Jun. 2025 ($0.10 Mil) but then increased from Jun. 2025 ($0.10 Mil) to Sep. 2025 ($0.14 Mil).

Lipella Pharmaceuticals's annual Current Accrued Expense declined from Dec. 2022 ($0.46 Mil) to Dec. 2023 ($0.11 Mil) but then increased from Dec. 2023 ($0.11 Mil) to Dec. 2024 ($0.32 Mil).

Lipella Pharmaceuticals Current Accrued Expense Related Terms

Lipella Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Lipella Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipella Pharmaceuticals Current Accrued Expense Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
0.05 0.23 0.46 0.11 0.32

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.32 0.36 0.10 0.14

Lipella Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.14 Mil mean?
Lipella Pharmaceuticals (LIPO) has a Current Accrued Expense of $0.14 Mil as of Sep. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on Lipella Pharmaceuticals and its competitors.
Is Lipella Pharmaceuticals' Current Accrued Expense too high?
Lipella Pharmaceuticals' current Current Accrued Expense is $0.14 Mil.
How does Lipella Pharmaceuticals' Current Accrued Expense compare to SIGY and CNBX?
Lipella Pharmaceuticals' Current Accrued Expense of $0.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Lipella Pharmaceuticals and its competitors. Lipella Pharmaceuticals's current Current Accrued Expense is $0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.81, compared to a current price of $0.00 — trading 100% below its estimated fair value. The current Current Accrued Expense is $0.14 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current Current Accrued Expense is $0.14 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lipella Pharmaceuticals Business Description

Address 7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.